14,327 Shares in IQVIA Holdings Inc. $IQV Purchased by Bank of Nova Scotia

Bank of Nova Scotia purchased a new stake in IQVIA Holdings Inc. (NYSE:IQV) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 14,327 shares of the medical research company’s stock, valued at approximately $2,772,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. BlackRock Inc. purchased a new stake in shares of IQVIA during the second quarter worth $2,811,292,000. Boston Partners purchased a new position in shares of IQVIA in the third quarter valued at $676,698,000. Norges Bank bought a new stake in shares of IQVIA during the 4th quarter valued at $497,445,000. Victory Capital Management Inc. raised its stake in shares of IQVIA by 2,628.1% during the 4th quarter. Victory Capital Management Inc. now owns 1,675,479 shares of the medical research company’s stock valued at $377,670,000 after purchasing an additional 1,614,063 shares during the period. Finally, Orbis Allan Gray Ltd boosted its stake in IQVIA by 96.5% in the 4th quarter. Orbis Allan Gray Ltd now owns 1,901,091 shares of the medical research company’s stock worth $428,525,000 after purchasing an additional 933,554 shares during the period. 89.62% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on IQV shares. Barclays reiterated an “overweight” rating on shares of IQVIA in a research report on Tuesday, July 28th. TD Cowen boosted their price objective on shares of IQVIA from $233.00 to $288.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. Wall Street Zen raised shares of IQVIA from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. Robert W. Baird increased their target price on shares of IQVIA from $252.00 to $287.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 29th. Finally, Royal Bank Of Canada raised their price target on shares of IQVIA from $221.00 to $247.00 and gave the company an “outperform” rating in a report on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $241.88.

Insiders Place Their Bets

In other news, insider Keriann Cherofsky sold 558 shares of the firm’s stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $245.21, for a total value of $136,827.18. Following the completion of the sale, the insider directly owned 2,989 shares of the company’s stock, valued at approximately $732,932.69. This trade represents a 15.73% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Eric Sherbet sold 5,000 shares of IQVIA stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the sale, the insider directly owned 20,999 shares in the company, valued at $5,232,110.84. The trade was a 19.23% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 12,913 shares of company stock worth $3,098,793 in the last ninety days. Insiders own 1.70% of the company’s stock.

IQVIA Stock Performance

NYSE IQV opened at $261.57 on Thursday. IQVIA Holdings Inc. has a 52-week low of $154.50 and a 52-week high of $262.51. The company has a fifty day moving average of $218.41 and a 200-day moving average of $188.59. The company has a market capitalization of $43.05 billion, a P/E ratio of 32.45, a P/E/G ratio of 2.22 and a beta of 1.18. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The company had revenue of $4.37 billion during the quarter, compared to the consensus estimate of $4.30 billion. During the same quarter in the previous year, the company posted $2.81 EPS. IQVIA’s quarterly revenue was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, equities research analysts predict that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA announced that its Board of Directors has authorized a stock buyback program on Thursday, May 7th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the medical research company to purchase up to 6.8% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company’s leadership believes its shares are undervalued.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.